About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

AbbVie received FDA approval for a first in class, all oral, fixed duration regimen combining VENCLEXTA and acalabrutinib for previously untreated chronic lymphocytic leukemia. The company announced a ...

A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). The authors explained that while molecularly targeted therapies like Bruton ...

Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

Getting a diagnosis of leukemia can feel overwhelming. But multiple treatment options and support organizations can help you on your journey after diagnosis. Leukemia is a type of cancer that affects ...

The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...